retatrutide biolongevity labs PoundsPunch Periodical 2025.03: The Gray Market for "Research Use Only" Weight Loss Drugs Retatrutide, Part 2: Examining The

The action created a green list of facilities permitted to ship GLP-1 APIs

Tirzepatide (Dual GIP/GLP-1 Agonist) Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors: GLP-1 effects same appetite suppression and insulin sensitivity as semaglutide GIP receptor activation enhances fat metabolism and insulin secretion through a complementary pathway Synergistic signaling the dual mechanism produces greater metabolic effects than either pathway alone This dual agonism is why Tirzepatide has shown superior weight loss in head-to-head trials

The pathogenesis of polycystic ovary syndrome: the hypothesis of PCOS as functional ovarian hyperandrogenism revisited

A.Jansen SteurE